Enea TECH and Biomedical Foundation announced a €15 million investment in Tethis S.p.A., a Milan-based company at the forefront of cancer diagnostics. This new round follows previous investments from Genextra and Indaco Venture Partners.
Tethis is developing innovative solutions for liquid biopsy, a non-invasive blood test that can detect traces of tumor circulating in the blood. And Tethis’ innovation lies in its integrated analytical process that includes the See.d blood sample preparation instrument, SmartBioSurface slides treated with biocompatible nanomaterials, and AI algorithms for identifying cellular elements of tumor origin.
This platform characterizes immune cells and any circulating tumor cells, and to integrate cellular analysis with molecular markers present in plasma. And the goal is to support accurate tumor diagnosis, monitor disease during and after treatment, and hopefully detect tumors early.
KEY QUOTES:
“This investment will accelerate the development, validation and preparation for commercialization of our diagnostic platform. Starting with a simple blood draw, we aim to provide oncologists and translational researchers with comprehensive cellular and molecular analyses that advance precision diagnostics, enable targeted therapeutic development, and ultimately deliver more personalized care for cancer patients.”
- Holger Neecke, CEO of Tethis
“The investment of 15 million euros in Tethis is further confirmation of Italy’s central role as a leader in cutting-edge innovation, with a focus on precision medicine and advanced diagnostics. Supporting revolutionary technological solutions, such as liquid biopsy, means laying the groundwork for a future where faster, more accurate, and less invasive diagnoses can significantly improve the quality of life for cancer patients. Through this project, we renew our commitment to building an innovative and forward-thinking ecosystem that prioritizes the health and well-being of individuals while effectively addressing the increasingly complex challenges of our time.”
- Maria Cristina Porta, General Manager of ENEA Tech and Biomedical Foundation
